FDA complete response letter releases tighten disclosure and spotlight approval hurdles
The FDA’s publication of complete response letters has tightened company disclosure around drug rejections and exposed common approval hurdles. Analyses of the letters point to frequent facilities and product quality deficiencies and delays averaging more than 2.5 years to final approval.
The U.S. Food and Drug Administration has published complete response letters covering approval applications submitted from 2020 to 2025, a move that experts say has led to a shift in how companies communicate regulatory rejections. The policy has reduced the scope for companies’ explanations to diverge from the agency’s position, while the letters also offer a closer look at issues around clinical trial conduct, safety and efficacy, manufacturing, facilities and product quality that can sink filings.
Last July, the agency published more than 200 complete response letters covering approval applications submitted from 2020 to 2024. The FDA has continued to add to two repositories of rejection letters, one for drugs that are now approved and another for products that have yet to come to market. Officials have shared archived CRLs reaching as far back as the FDA’s 2002 rejection of depression drug gepirone, which ultimately won approval in 2023, and the FDA has also published recent rejections, including its February dismissal of a request for authorization.
According to the agency, approximately 40% of the time, sponsors do not reveal that they were required to complete additional clinical trials for safety or efficacy. A 2015 analysis by the FDA found companies frequently failed to disclose the agency’s concerns and requests for new clinical trials, and the FDA said sponsors often misrepresent the rationale for rejections. Today, a company that misrepresented the FDA’s rationale would quickly be contradicted by the CRL’s release on the agency’s openFDA server.
The archived CRLs offered a closer look at historical FDA rejections, but recent CRLs have made a bigger impact by ending reliance on sponsors for details of FDA rejections. Experts said the reception from the investment community has been unanimously positive and that the publication policy brings a level of accountability and professionalism while giving communication some guardrails.
The public letters remain redacted, which could lead to some amount of varying interpretation of the information provided. The letters also may fail to fully encapsulate years of agency interactions and communications, and minutes of meetings between drug developers and the FDA remain private.
Analysis of the first set of over 200 CRLs for drugs that were eventually approved found that over half of the deficiencies identified fell into two categories: facilities and product quality. Other deficiencies included clinical efficacy, safety profile, labeling and patent concerns. More than half of facility-related deficiencies occurred because the FDA could not complete the required preapproval inspections.
On average, more than 2.5 years had passed between the initial CRL publication date and the final approval date. For a company launching their first drug, this extended approval timeline could result in a substantial increase in time to commercialization and, in many instances, increase launch costs.